MarketPulse

systemic lupus erythematosus

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Cullinan's CD19 T Cell Engager Shows Promise in Autoimmune Disease

Cullinan Therapeutics to present Phase 1 data for CLN-978 at EULAR 2026, demonstrating favorable safety and B cell depletion in treatment-refractory rheumatoid arthritis and lupus.
CGEMbiopharmaceuticalPhase 1 clinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

LBL-047 Advances to Clinical Testing for Autoimmune Diseases as Dianthus Raises $719M

Nanjing Leads Biolabs and Dianthus Therapeutics advance LBL-047, a bifunctional fusion protein, into Phase 1 trials for three autoimmune conditions with $719M in funding.
DNTHclinical developmentautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

SLE Drug Market to Nearly Triple to $5.9B by 2034 as New Therapies Challenge Generics

SLE drug market projected to grow nearly 150% to $5.9B by 2034 on new therapies, but biosimilar competition and pricing pressure could limit upside.
BMYCELGrABBVNVSRHHBY+3market forecastbiosimilars
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

SLE Drug Race Heats Up: 120+ Pharma Giants Develop 140+ Pipeline Therapies

Over 120 pharmaceutical companies are developing 140+ drugs for systemic lupus erythematosus, with major players like Roche and Novartis advancing promising new treatment mechanisms.
JNJABBVNVSRHHBYAZN+3FDA approvalclinical trials